Demystifying Resistant Hypertension: Practice Pearls for the Outpatient Clinician

Introduction

Hypertension is one of the most common modifiable risk factors for cardiovascular disease in the outpatient setting. Although blood pressure (BP) can be controlled with standard treatment regimens in many patients, achieving or maintaining BP control is particularly challenging in patients with resistant hypertension (RH).

Resistant hypertension is defined as BP that remains above goal despite the concurrent use of 3 antihypertensive agents of different classes (commonly a long-acting calcium channel blocker, a renin-angiotensin system blocker, and a diuretic) administered at maximally tolerated doses. It also includes patients whose BP is controlled but requires 4 or more medications. Navigating RH requires a systematic approach, progressing from diagnosis validation to targeted pharmacotherapy and newer interventions.¹

Epidemiology

Understanding the demographic and risk profile of RH is critical for the outpatient clinician:

• Patients with RH had a 47% higher adjusted risk of a composite outcome comprising death or incident myocardial infarction, heart failure, stroke, or chronic kidney disease (CKD) compared with patients without RH.¹
• Patients with RH had a 32% higher adjusted risk of developing end-stage kidney disease compared with patients without RH.¹
• Apparent treatment resistance may reflect pseudo-resistance caused by inaccurate BP measurement, the white-coat effect, or medication nonadherence.¹
• Secondary causes of hypertension are more common among patients with RH than among the broader hypertensive population.¹
• OSA is highly prevalent among patients with RH, with reported prevalence estimates reaching approximately 70%-90%.

The following clinical pearls provide a practical framework for evaluating and managing apparent resistant hypertension in the outpatient setting. They address confirming true treatment resistance, identifying reversible and secondary causes, optimizing established pharmacologic therapy, and considering newer medications or device-based interventions when appropriate.

Pearl #1: Rule Out "Pseudo-Resistance" First

Before escalating therapy, clinicians must verify that the resistance is real. Up to 50% of patients diagnosed with RH in the clinic have "apparent" or pseudo-resistant hypertension.¹

• Master the Measurement: Improper BP technique (eg, using a cuff that is too small, measuring over clothing, or failing to let the patient rest for 5 minutes) frequently artificially inflates readings.¹
• Defeat the White Coat: Nearly a third of apparent RH patients have the "white-coat effect." Securing out-of-office measurements via 24-hour ambulatory blood pressure monitoring or rigorous home blood pressure monitoring is strongly recommended before making a diagnosis of true RH.¹
• Assess Adherence: Pill burden, side effects, and cost drive non-adherence. Fostering a non-judgmental dialogue (eg, "Many of my patients find taking 4 pills a day frustrating. How many doses do you estimate you miss in a typical week?") yields far better diagnostic accuracy than simply asking if they take their medications. Consider transitioning to single-pill combination therapies whenever possible to reduce pill burden.¹

Pearl #2: Optimize the Diuretic (The Nephrologist’s Secret)

Suboptimal volume management is the most common iatrogenic cause of RH. The kidneys adapt to multidrug regimens by enhancing sodium retention, making a potent diuretic the linchpin of RH management.¹

• Upgrade the Thiazide: Hydrochlorothiazide (HCTZ) is often prescribed by default but has a short half-life that leaves patients unprotected during the night. Switching from HCTZ to a long-acting thiazide-like diuretic—specifically chlorthalidone (12.5–25 mg daily) or indapamide (1.25–2.5 mg daily)—provides superior 24-hour BP control.¹
• The CLICK Trial Paradigm Shift: Historically, medical dogma dictated that thiazides lose their efficacy as the estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73 m². The landmark CLICK (Chlorthalidone in Chronic Kidney Disease) trial emphatically overturned this idea. The study demonstrated that chlorthalidone substantially reduces 24-hour ambulatory BP and significantly lowers proteinuria in patients with stage 4 CKD. While a loop diuretic (such as torsemide, preferred for its reliable oral bioavailability) may still be required to manage overt fluid overload, chlorthalidone remains an effective, practice-changing tool for RH even in advanced kidney disease.²

Pearl #3: Screen Pragmatically for Secondary Causes

While essential hypertension dominates, the prevalence of secondary hypertension jumps to 10-20% in the RH population.¹

• Obstructive Sleep Apnea (OSA): OSA is highly prevalent among patients with RH, with reported prevalence estimates reaching approximately 70%-90%.¹ The resulting sympathetic surge and RAAS activation notoriously drive refractory nighttime and early morning hypertension. Screen aggressively and refer for polysomnography.¹
• Primary Aldosteronism (PA): PA is vastly underdiagnosed. Screen patients with RH using a plasma aldosterone-to-renin ratio, especially if there is unprovoked hypokalemia (though normokalemic PA is common). In fact, the 2025 ACC/AHA guideline specifically recommends screening all adults with resistant hypertension for primary aldosteronism regardless of whether hypokalemia is present.^1,3
• Interfering Substances: Routinely review the medication list for stealth BP elevators: NSAIDs, oral contraceptives, sympathomimetics (decongestants), SNRIs (like venlafaxine), and excessive alcohol consumption.¹

Pearl #4: Maximize RAAS Blockade (MRAs and ASIs)

When a patient remains uncontrolled on a maximized three-drug regimen (ACEi/ARB + calcium channel blocker + optimized diuretic), the next step is targeting aldosterone.¹

• The Mineralocorticoid Receptor Antagonist (MRA) Standard: The landmark PATHWAY-2 trial demonstrated that spironolactone (25–50 mg daily) is superior to beta-blockers or alpha-blockers as a fourth-line agent for RH. By directly antagonizing the aldosterone escape that occurs with chronic ACEi/ARB use, spironolactone profoundly lowers BP. Monitor basic metabolic panels within 1-2 weeks of initiation, particularly in patients with CKD, to rule out hyperkalemia.^1,4
• Clinical Caveat (The Gynecomastia Dilemma): Because spironolactone is a non-selective MRA, up to 10% of men may develop painful gynecomastia or breast tenderness. If this dose-limiting adverse effect occurs, guidelines recommend switching to the highly selective MRA, eplerenone (Inspra), or to the potassium-sparing epithelial sodium channel blocker, amiloride, as effective, better-tolerated alternatives.^1,4
• Aldosterone Synthase Inhibitors (ASIs): Emerging on the horizon are highly selective ASIs, such as baxdrostat, approved by the FDA in May 2026.⁵ Rather than blocking the mineralocorticoid receptor, these agents directly inhibit CYP11B2, thereby suppressing aldosterone production at the source.⁶ ASIs could serve as a powerful, targeted alternative for refractory patients.

Pearl #5: Integrate Novel Pharmacologic Agents

For decades, the pharmacological pathways used to treat hypertension remained static. That changed recently with the targeting of the endothelin system.

• Aprocitentan (Tryvio): Approved by the FDA in March 2024, aprocitentan is an oral dual endothelin-1 receptor antagonist explicitly indicated for resistant hypertension. Based on the Phase 3 PRECISION trial, it offers a novel mechanism of action for patients uncontrolled on multiple agents.⁷
• Clinical Caveat: The primary side effect of endothelin antagonism is fluid retention and edema. This side effect makes the concurrent optimization of your diuretic base (as discussed in Pearl #2) critical when initiating aprocitentan.⁷

Pearl #6: Consider Device-Based Therapies

For patients with refractory hypertension, despite maximal pharmacotherapy, or those with severe medication intolerance, device-based therapies have entered the clinical arena.⁷

• Renal Denervation (RDN): In late 2023, the FDA approved 2 minimally invasive RDN systems (utilizing radiofrequency and ultrasound energy). These systems are indicated as adjunctive treatments to reduce blood pressure in patients with hypertension whose blood pressure is not adequately controlled with lifestyle modifications and antihypertensive medications. By ablating the overactive sympathetic nerves surrounding the renal arteries, RDN disrupts a key neurohormonal driver of hypertension. Clinical trials have demonstrated sustained, "always-on" blood pressure reductions (averaging a ~9-10 mmHg drop in office systolic BP) without the adherence challenges associated with daily medications.⁸

Conclusion

Managing resistant hypertension is an exercise in meticulous primary care combined with an awareness of evolving therapeutics. By confirming medication adherence, optimizing the diuretic base regardless of CKD stage, deploying an MRA as the fourth-line agent, and recognizing when to consider novel therapies such as endothelin receptor antagonists or RDN, the outpatient clinician can mitigate cardiovascular risk and improve patient outcomes.

References

1. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53-e90. doi:10.1161/HYP.0000000000000084
2. Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021;385(27):2507-2519. doi:10.1056/NEJMoa2110730
3. Jones DW, Ferdinand KC, Taler SJ, et al. 2025 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Circulation. Published online August 14, 2025. doi:10.1161/CIR.0000000000001356.
4. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-2068. doi:10.1016/S0140-6736(15)00257-3
5. Calabro A. FDA approval granted for baxdrostat (Baxfendy) for adults with uncontrolled hypertension. Consultant360. Published May 2026. Accessed September 8, 2026. https://www.consultant360.com/fda-alerts/fda-approval-granted-baxdrostat-baxfendy-adults-uncontrolled-hypertension
6. Freeman MW, Halvorsen YD, Marshall W, et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388(5):395-405. doi:10.1056/NEJMoa2213169
7. Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400(10367):1927-1937. doi:10.1016/S0140-6736(22)02034-7
8. Cluett JL, Blazek O, Brown AL, et al. Renal denervation for the treatment of hypertension: a scientific statement from the American Heart Association. Hypertension. 2024;81(10):e135-e148. doi:10.1161/HYP.0000000000000240

AUTHOR
Anand Ravindran, MD¹

AFFILIATION
¹Primary Care Patient Aligned Care Team (PACT) Physician, Toledo VA Community-Based Outpatient Clinic (CBOC), Toledo, OH, USA

CITATION
Ravindran A. Demystifying resistant hypertension: practice pearls for the outpatient clinician. Consultant360. Published online: September 8, 2026.

DISCLOSURE
The author reports no relevant financial relationships.

DISCLAIMER
The views expressed in this article are those of the author and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government.

CORRESPONDENCE
Anand Ravindran, MD, Toledo VA Clinic, 1200 South Detroit Avenue, Toledo, OH 43614-5903 (email: amravindran@aol.com)

©2026 HMP Global. All Rights Reserved. Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Consultant360 or HMP Global, their employees, and affiliates.